STOCK TITAN

Gilead Sciences Comments on the Passing of John C. Martin, PhD

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Gilead Sciences (Nasdaq: GILD) announced the passing of John C. Martin, PhD, former CEO from 1996-2016 and chairman from 2008-2019. His leadership transformed Gilead, enhancing access to treatments and driving growth. Martin, who joined Gilead in 1990, left a lasting legacy in biopharmaceuticals, impacting millions of patients globally. Current CEO Daniel O’Day expressed deep condolences, highlighting Martin’s significant contributions to scientific advancements. Gilead continues to focus on innovative medicines for serious diseases like HIV, hepatitis, and cancer, operating in over 35 countries worldwide.

Positive
  • John C. Martin's leadership from 1996 to 2016 contributed to remarkable company growth.
  • Martin played a key role in expanding access to life-saving medications globally.
Negative
  • None.

Gilead Sciences, Inc. (Nasdaq: GILD) today released the following statement on the death of John C. Martin, PhD, who served as the company’s chief executive officer from 1996 to 2016 and as its chairman from 2008 to 2019.

It is with great sadness that the company has learned of the passing of Dr. Martin, whose scientific vision and leadership helped transform the lives of millions of patients and shape Gilead into the company that it is today. John began his career at Gilead in 1990, as vice president of Research & Development. As chief executive officer from 1996 through 2016, he steered the company through a period of remarkable growth.

“John’s legacy will be felt for generations to come, living on through the scientific progress made under his leadership and the programs he championed that expanded access to medications for people around the world,” said Daniel O’Day, Chairman and Chief Executive Officer, Gilead Sciences. “On behalf of all of us at Gilead, I extend our deepest condolences to John’s family.”

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

FAQ

What was John C. Martin's role at Gilead Sciences?

John C. Martin served as CEO from 1996 to 2016 and chairman from 2008 to 2019.

How did John C. Martin impact Gilead Sciences?

He transformed the company and significantly enhanced access to treatments for millions of patients.

What is Gilead Sciences known for?

Gilead Sciences is known for developing innovative medicines for serious diseases like HIV, hepatitis, and cancer.

When did John C. Martin pass away?

The press release does not specify the exact date of John C. Martin's passing.

Gilead Sciences Inc

NASDAQ:GILD

GILD Rankings

GILD Latest News

GILD Stock Data

114.57B
1.24B
0.12%
88.4%
1.45%
Drug Manufacturers - General
Biological Products, (no Disgnostic Substances)
Link
United States of America
FOSTER CITY